Highlights of This Issue 2721

SPECIAL FEATURES

CCR Translations

2723 Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Michael Pollak
See article p. 2905

Molecular Pathways

2726 Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.B. Seftor, and Mary J.C. Hendrix

CCR Focus

2734 Progress in Pediatric Cancer
Susan E. Bates

2735 Genetically InFormed Therapies—A "GIFT" for Children with Cancer
Carol J. Thiele and Susan L. Cohn

2740 Promising Therapeutic Targets in Neuroblastoma
Katharine K. Matthay, Rani E. George, and Alice L. Yu

2754 Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy
Mignon L. Loh and Charles G. Mullighan

2768 Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Elizabeth R. Lawlor and Carol J. Thiele

2770 The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp

2779 Using Germline Genomics to Individualize Pediatric Cancer Treatments
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

Perspective

2801 Disrupting the Networks of Cancer
Daniel F. Camacho and Kenneth J. Pienta

Review

2809 Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?
Peter H. O'Donnell and Walter M. Stadler

HUMAN CANCER BIOLOGY

2817 Suppression of Skeletal Muscle Turnover in Cancer Cachexia: Evidence from the Transcriptome in Sequential Human Muscle Biopsies

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2838</td>
<td>Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients</td>
<td>Daniela Speisky, Aurélie Duces, Ivan Béche, Vinciane Rebour, Pascal Hammel, Alain Sauvanet, Stéphane Richard, Pierre Bedossa, Michel Vidaud, Arnaud Murat, Patricia Niccoli, Jean-Yves Scouezé, Philippe Ruszniewski, and Anne Couvelard for the GTE Group (Groupe d’Étude des Tumeurs Endocrines)</td>
</tr>
<tr>
<td>2861</td>
<td>L-BLP25 Vaccine plus Letrozole Induces a Th1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice</td>
<td>Neelima R. Mehta, Gregory T. Wurz, Rebekah A. Burich, Brittany E. Greenberg, Stephen Griffey, Audrey Gutierrez, Katie E. Bell, Jamie L. McCall, Michael Wolf, and Michael DeGregorio</td>
</tr>
<tr>
<td>2872</td>
<td>Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study</td>
<td>Harri Sihto, Tom Böhlöing, Heli Kavola, Virve Koljonen, Marko Salmi, Sirpa Jalkanen, and Heikki Joensuu</td>
</tr>
<tr>
<td>2882</td>
<td>Global Methylation Profiling for Risk Prediction of Prostate Cancer</td>
<td>Saswati Mahapatra, Eric W. Klee, Charles Y.F. Young, Zhifu Sun, Rafael E. Jimenez, George G. Klee, Donald J. Tindall, and Krishna Vanaja Donkena</td>
</tr>
<tr>
<td>2896</td>
<td>Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinicopathologic Features of Prostate Cancer</td>
<td>Ken Kron, Liyang Liu, Dominique Trudel, Vajjayanti Pethe, John Trachtenberg, Neil Fleshner, Bharati Bapat, and Theodorus van der Kwast</td>
</tr>
<tr>
<td>2895</td>
<td>Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer</td>
<td>Navid Sadeghi, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li</td>
</tr>
<tr>
<td>2913</td>
<td>Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron</td>
<td>Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O’Mahony, Peter Donachie, and Julian Howell</td>
</tr>
<tr>
<td>2922</td>
<td>Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience</td>
<td>Jennifer Wheeler, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchuck, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Betzky Stephen, Sijin Wen, and Razelle Kurzrock</td>
</tr>
</tbody>
</table>
Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer
Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudio Coco, Giovanni Scambia, Shohreh Shahabi, and Cristiano Ferlini

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Florence de Fraipont, Guénaëlle Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer
Shouyu Wang, Xuming Wu, Yansu Chen, Jianbing Zhang, Jingjing Ding, Yan Zhou, Song He, Yongfei Tan, Fulin Qiang, Jin Bai, Jinyan Zeng, Zhenghua Gong, Aiping Li, Gang Li, Oluf Dimitri Røe, and Jianwei Zhou

ABOUT THE COVER
Methylation of the tumor suppressor gene Ras association domain family 1A (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluo red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.